Pietro Scilipoti

ORCID: 0009-0007-6126-9889
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Prostate Cancer Treatment and Research
  • Urinary and Genital Oncology Studies
  • Prostate Cancer Diagnosis and Treatment
  • Renal cell carcinoma treatment
  • Urological Disorders and Treatments
  • Health Systems, Economic Evaluations, Quality of Life
  • Renal and Vascular Pathologies
  • Economic and Financial Impacts of Cancer
  • Cancer Immunotherapy and Biomarkers
  • Genetic factors in colorectal cancer
  • Multiple and Secondary Primary Cancers
  • Urologic and reproductive health conditions
  • Renal and related cancers
  • Esophageal Cancer Research and Treatment
  • Infectious Disease Case Reports and Treatments
  • Colorectal Cancer Screening and Detection
  • Colorectal Cancer Surgical Treatments
  • Cancer Genomics and Diagnostics
  • Cancer Research and Treatments
  • Cardiac, Anesthesia and Surgical Outcomes
  • Radiomics and Machine Learning in Medical Imaging
  • MRI in cancer diagnosis
  • Pancreatic and Hepatic Oncology Research
  • Chronic Kidney Disease and Diabetes

IRCCS Ospedale San Raffaele
2024-2025

Vita-Salute San Raffaele University
2024-2025

Uppsala University
2024-2025

Uppsala University Hospital
2025

Istituti di Ricovero e Cura a Carattere Scientifico
2023-2025

Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2024-2025

Surgical Science (Sweden)
2025

San Raffaele University of Rome
2025

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2022

To assess the oncological outcomes of patients with high-risk (HR) and very (VHR) non-muscle-invasive bladder cancer (NMIBC) treated upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations from a contemporary European multicentre cohort. We conducted retrospective analysis 1491 diagnosed HR- or VHR-NMIBC database between 2015 2024. Patients were included if they received either RC at least five doses BCG. A 1:1 propensity score matching (PSM) according to clinically...

10.1111/bju.16675 article EN BJU International 2025-02-18

Objective To assess the diagnostic performance of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa). Materials Methods This analysis was based on a cohort 199 BCa patients undergoing RC bilateral PLND between 2015 2022. Neoadjuvant chemotherapy (NAC) or immunotherapy (NAI) administered after oncological evaluation. All received...

10.1111/bju.16363 article EN cc-by-nc-nd BJU International 2024-04-15

Retzius-sparing (RS) robot-assisted radical prostatectomy represents a valid surgical treatment option for prostate cancer (PCa) patients. However, the available evidence on role of RS in high-risk (HR) PCa setting is sparse.To describe our technique HR-PCa patients and to evaluate intra-, peri-, postoperative oncological functional outcomes.A total 340 D'Amico underwent at single high-volume centre between 2011 2020.Surgical procedures were performed by five experienced robotic...

10.1016/j.euros.2022.02.007 article EN cc-by-nc-nd European Urology Open Science 2022-03-04

Objective To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort patients with high‐risk very‐high‐risk non‐muscle‐invasive bladder cancer (NMIBC) after previous Bacillus Calmette–Guérin (BCG) treatment. Materials Methods Data were retrospectively collected from 95 NMIBC, treated Gem/Doce at 12 centres between 2021 2024. Patients previously BCG who had completed full induction course received least one...

10.1111/bju.16645 article EN BJU International 2025-01-11

Abstract Background There has been a wide range in incidence of prostate-specific antigen (PSA) persistence and relapse after radical prostatectomy (RP) for prostate cancer (PCa). We aimed to describe prognostic implications PSA relapse. Methods Register-based cohort study Sweden men diagnosed with PCa between 2007 2020 who underwent RP. Risks were estimated using competing risk cumulative curves. Treatment or death other causes stratified according persistence, European Association Urology...

10.1093/jnci/djaf012 article EN cc-by JNCI Journal of the National Cancer Institute 2025-01-17

Swedish national guidelines provide evidence-based recommendations for standard of care; however, little is known about adherence to them. The aim this study was assess management prostate cancer (PCa). Data in the National Prostate Cancer Register (NPCR), that includes 98% all incident PCa cases Sweden, were used analyse men diagnosed between 2010 and 2023. A selection quality indicators displayed on public web page NPCR assessed. Active surveillance with low-risk an estimated life...

10.2340/sju.v60.43107 article EN cc-by Scandinavian Journal of Urology 2025-02-27

Objective To assess the incidence of acute kidney injury (AKI) and disease (AKD) following radical cystectomy (RC) in patients with muscle‐invasive bladder cancer (BCa). Materials Methods A consecutive cohort 840 undergoing RC for BCa at a tertiary institution (2010–2022) was analysed. Clinical variables, comorbidities, surgical techniques oncological regimens were recorded pre‐ post‐surgery. Serum creatinine estimated glomerular filtration rate (eGFR) assessed baseline, 24, 48 72 h, 6 days...

10.1111/bju.16696 article EN BJU International 2025-03-21

To evaluate the impact of discordant histological diagnoses between transurethral resection bladder tumour (TURBT) and radical cystectomy (RC) on cancer-specific mortality (CSM) in patients with cancer (BCa). We relied a multi-institutional database collecting data BCa who underwent TURBT subsequent RC from nine centres 2000 2023. tested concordance rates detecting urothelial carcinoma urinary (UCUB) as well non-UCUB hystological subtypes, using reference standard. Concordance was defined...

10.1111/bju.16714 article EN BJU International 2025-03-26

Background/Objectives: An 80-year-old man was admitted to our department after a salvage radical cystectomy for actinic cystitis due radiotherapy prostate cancer. He presented with two-month history of feculent debris in the right stoma and deteriorated general conditions, long past medical recurrent complicated urinary infections. Methods: Computer tomography (CT) abdomen revealed ureterocolic fistula along ureteral pelvic tract. A percutaneous nephrostomy tube placed. Due multiple previous...

10.3390/std14020011 article EN cc-by Surgical Techniques Development 2025-04-01

Trimodality therapy (TMT) with transurethral resection followed by radiation of the urinary bladder and chemotherapy is associated similar long-term survival rates to radical cystectomy (RC) for well-selected patients. Nevertheless, salvage RC may become necessary in 10% patients receiving TMT. We aimed assess perioperative outcomes after prior TMT through a large multinational cohort study. included pure urothelial cancer bladder. Patients undergoing due recurrence from 13 high-volume...

10.1016/j.euf.2025.04.028 article EN cc-by European Urology Focus 2025-04-01

Objective To report real‐world rates of non‐muscle‐invasive bladder cancer (NMIBC) recurrence and progression within a European multicentre cohort with detailed information on intravesical instillation courses, as contemporary data oncological outcomes in NMIBC are limited. Patients methods A total 1918 patients treated transurethral resection tumour (TURBT) were retrospectively identified from six tertiary‐referral centres (2015–2022). stratified according to Association Urology 2021...

10.1111/bju.16780 article EN cc-by-nc BJU International 2025-05-21
Coming Soon ...